問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

Recruiting

List

917Cases

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2020-08-01 - 2022-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-04-12 - 2028-04-12

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-08-01 - 2025-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-08-01 - 2023-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-04-01 - 2025-12-31

Phase II

Modeling the relationships between functional connectivity and amyloid deposition in Alzheimer’s disease

  • Condition/Disease

    Alzheimer’s disease

  • Test Drug

    F-18 AV-45

Participate Sites
2Sites

Recruiting2Sites

2017-11-01 - 2021-12-08

Phase III

Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)

  • Condition/Disease

    Acute primary cerebral hemorrhage

  • Test Drug

    Three-dose combination(telmisartan, amlodipine, indapamide)

Participate Sites
4Sites

Recruiting3Sites

Study ended1Sites

李宗海
Linkou Chang Gung Medical Foundation

Division of Neurology

2018-11-01 - 2022-04-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    Baricitinib

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2020-06-01 - 2022-01-31

Phase III

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    Baricitinib

Participate Sites
9Sites

Recruiting9Sites

2019-08-07 - 2023-04-30

Phase III

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial

  • Condition/Disease

    Cholangiocarcinoma

  • Test Drug

    Infigratinib(BGJ398)

Participate Sites
8Sites

Recruiting8Sites

1 78 79 80 81 82 92
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB